ArticleHaematologica2026

Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti- CD38 monoclonal antibodies: outcomes from a real-world experience.

Carmine Liberatore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.